Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Stenocare AS's enterprise value is €5.53 Mil.
Stenocare AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €0.03 Mil. Therefore, Stenocare AS's EV-to-EBITDA for today is 204.63.
The historical rank and industry rank for Stenocare AS's EV-to-EBITDA or its related term are showing as below:
FRA:S7C'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -185.77 Med: -7.13 Max: 1168.95
Current: 201.48
During the past 8 years, the highest EV-to-EBITDA of Stenocare AS was 1168.95. The lowest was -185.77. And the median was -7.13.
FRA:S7C's EV-to-EBITDA is ranked worse than 98.09% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.435
vs FRA:S7C: 201.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stenocare AS's PE Ratio (TTM) for today is calculated as:
Stenocare AS's share price for today is €0.1205.
Stenocare AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Stenocare AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S7C vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Stenocare AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stenocare AS EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Stenocare AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Stenocare AS's EV-to-EBITDA falls into.
Stenocare AS's current Enterprise Value is €5.53 Mil.
Stenocare AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stenocare AS (FRA:S7C) has a EV-to-EBITDA of 204.63 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stenocare AS. According to the industry distribution chart, Stenocare AS ranks #720 out of 734 companies in the Drug Manufacturers industry, placing it in the top 98.1%.
Is Stenocare AS's EV-to-EBITDA too high?
Stenocare AS's current EV-to-EBITDA is 204.63. The Drug Manufacturers industry median EV-to-EBITDA is 13.44. Stenocare AS's value of 204.63 is 1423.1% above this industry median. Based on the distribution chart, Stenocare AS ranks #720 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Stenocare AS has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Stenocare AS's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Stenocare AS ranks #720 out of 734 companies for EV-to-EBITDA. This places Stenocare AS in the lower half of its industry. The industry median EV-to-EBITDA is 13.44. Stenocare AS's value of 204.63 is 1423.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.44, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stenocare AS's current EV-to-EBITDA of 204.63 is 1423.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stenocare AS. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stenocare AS's current EV-to-EBITDA is 204.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stenocare AS stock overvalued right now?
Stenocare AS (FRA:S7C) has a current EV-to-EBITDA of 204.63. The stock's GF Value™ is €0.30, compared to a current price of €0.12 — trading 59.8% below its estimated fair value. The current EV-to-EBITDA is 204.63 and 1423.1% above the Drug Manufacturers industry median of 13.44. Stenocare AS's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Stenocare AS (FRA:S7C), the current EV-to-EBITDA is 204.63 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stenocare AS (FRA:S7C) Overvalued in 2026?
Based on GuruFocus' analysis, Stenocare AS stock appears to be undervalued.
The current stock price of €0.12 is trading 59.8% below its estimated GF Value™ of €0.30.
Key valuation signals for FRA:S7C:
EV-to-EBITDA: 204.63
GF Value™: €0.30 vs. price of €0.12 (59.8% below fair value)
Industry Position: 1423.1% above the Drug Manufacturers median (#720 of 734)
No single metric tells the full story. See the FRA:S7C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
39GF Score
Get the complete analysis for FRA:S7C
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S7C has been successfully added to your 
